Episode 197: Robert Califf's FDA return, the future of CRISPR, & another vaccine delay
Will there be a new ALS drug this year? What business does Wall Street have with CRISPR? And when can kids get Covid-19 vaccines?\n\nWe cover all that and more this week. First, STAT's Nicholas Florko joins us to preview the trials ahead for Robert Califf as he retakes the reins at the FDA \u2014 including a high-profile decision on a new treatment for ALS. Then, CRISPR pioneer Jennifer Doudna and financier Marty Chavez join us to talk about the future of genome editing and the investments they plan to make in it. We also discuss the latest on Eric Lander, the Covid-19 vaccine meeting that wasn't, and the future of Chinese-developed cancer drugs.